Current Report Filing (8-k)
04 February 2016 - 7:59AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________
FORM 8-K
___________
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 28, 2016
OPIANT PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Nevada |
|
000-55330 |
|
46-4744124 |
(State or other jurisdiction of
incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
445 Park
Avenue, 9th Floor, New York, NY 10022
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including
area code: (212) 829-5546
Lightlake Therapeutics, Inc.
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.03 Amendments to Articles of Incorporation or Bylaws;
Changes in Fiscal Year
On January 28, 2016, Lightlake Therapeutics
Inc. (the “Company”) filed a certificate of amendment to its Articles of Incorporation with the Secretary of State
of the State of Nevada changing the Company’s name to “Opiant Pharmaceuticals, Inc.” A copy of the certificate
of amendment is attached as Exhibit 3.1 to this report and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following exhibits are
filed as part of this report:
Exhibit
Number |
|
Description |
|
|
|
3.1 |
|
Certificate of Amendment to Articles of Incorporation, dated January 28, 2016. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
Opiant Pharmaceuticals, Inc. |
|
|
|
Dated: February 3, 2016 |
By: |
/s/ Dr. Roger Crystal |
|
|
Name: |
Dr. Roger Crystal |
|
|
Title: |
President and Chief Executive Officer |
Exhibit 3.1
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Apr 2024 to May 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From May 2023 to May 2024